A092730 Stock Overview
Engages in the manufacturing and sale of skin care products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
NeoPharm CO., LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩12,890.00 |
| 52 Week High | ₩17,150.00 |
| 52 Week Low | ₩10,075.00 |
| Beta | 0.77 |
| 11 Month Change | 2.30% |
| 3 Month Change | 21.32% |
| 1 Year Change | 10.41% |
| 33 Year Change | -0.85% |
| 5 Year Change | -44.97% |
| Change since IPO | 210.31% |
Recent News & Updates
The Returns On Capital At NeoPharm (KOSDAQ:092730) Don't Inspire Confidence
Nov 13
NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some Investors
Sep 13NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return Trends
Aug 07Recent updates
The Returns On Capital At NeoPharm (KOSDAQ:092730) Don't Inspire Confidence
Nov 13NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some Investors
Sep 13NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return Trends
Aug 07NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Jun 13Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price
Apr 24NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem
Mar 25Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Mar 28What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Mar 15How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?
Mar 02We're Watching These Trends At NeoPharm (KOSDAQ:092730)
Feb 18We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings
Feb 08
NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock
Jan 26An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued
Jan 15Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?
Jan 04NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Dec 24What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Dec 15Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Dec 04Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?
Nov 23Shareholder Returns
| A092730 | KR Personal Products | KR Market | |
|---|---|---|---|
| 7D | -5.0% | -10.8% | -6.0% |
| 1Y | 10.4% | -11.3% | -4.4% |
Return vs Industry: A092730 exceeded the KR Personal Products industry which returned -11.3% over the past year.
Return vs Market: A092730 exceeded the KR Market which returned -4.4% over the past year.
Price Volatility
| A092730 volatility | |
|---|---|
| A092730 Average Weekly Movement | 6.2% |
| Personal Products Industry Average Movement | 6.6% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A092730 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A092730's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 172 | Byeong-Deog Park | www.neopharm.co.kr |
NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand.
NeoPharm CO., LTD. Fundamentals Summary
| A092730 fundamental statistics | |
|---|---|
| Market cap | ₩201.62b |
| Earnings (TTM) | ₩22.93b |
| Revenue (TTM) | ₩107.86b |
8.8x
P/E Ratio1.9x
P/S RatioIs A092730 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A092730 income statement (TTM) | |
|---|---|
| Revenue | ₩107.86b |
| Cost of Revenue | ₩41.22b |
| Gross Profit | ₩66.64b |
| Other Expenses | ₩43.71b |
| Earnings | ₩22.93b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.47k |
| Gross Margin | 61.79% |
| Net Profit Margin | 21.26% |
| Debt/Equity Ratio | 0% |
How did A092730 perform over the long term?
See historical performance and comparison